Niagen Bioscience Stock Forecast
NASDAQ: NAGEHealth Care Medicinal Chemicals and Botanical Products USD
Market open · Delayed 15 min · as of Oct 9, 9:42 AM ET
NAGE analyst consensus
Consensus (6 analysts)
strong_buy
Avg. price target
$12.08+348.24%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Niagen Bioscience (2026-10-08), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $12.08, with a high estimate of $22.00 and a low estimate of $8.50. The average target implies upside of 348.2% from the current price of $2.70.
The spread between the highest and lowest targets is 158.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NAGE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 6 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.50 | +215.40% |
| Average target | $12.08 | +348.24% |
| High target | $22.00 | +716.33% |